SCHEMBL125577

SCHEMBL125577

O=C(O)CCCCCNC(=O)OCc1ccccc1

nearest known ligand 0.88

Predicted protein targets (top 13)

geneUniProtsupporting neighboursconfidence
HTT P42858 1/20 0.88
TGM2 P21980 1/20 0.68
FOLH1 Q04609 6/20 0.64
LMNA P02545 1/20 0.63
SMN1; SMN2 Q16637 1/20 0.63
KEAP1 Q14145 2/20 0.61
NFE2L2 Q16236 2/20 0.61
KMT2A Q03164 2/20 0.60
PTGER4 P35408 3/20 0.57
MEN1 O00255 1/20 0.55
TPSAB1 Q15661 1/20 0.55
TPSD1 Q9BZJ3 1/20 0.55
TPSG1 Q9NRR2 1/20 0.55

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8674198 1.00 HTT (0.88) HTTTGM2FOLH1LMNASMN1; SMN2
SCHEMBL2876850 1.00 HTT (0.88) HTTTGM2FOLH1LMNASMN1; SMN2
SCHEMBL3693087 1.00 HTT (0.88) HTTTGM2FOLH1LMNASMN1; SMN2
SCHEMBL3287016 1.00 HTT (0.88) HTTTGM2FOLH1LMNASMN1; SMN2
SCHEMBL3694316 1.00 HTT (0.88) HTTTGM2FOLH1LMNASMN1; SMN2
SCHEMBL4857273 1.00 HTT (0.88) HTTTGM2FOLH1LMNASMN1; SMN2
SCHEMBL4858734 1.00 HTT (0.88) HTTTGM2FOLH1LMNASMN1; SMN2
SCHEMBL2875581 1.00 HTT (0.88) HTTTGM2FOLH1LMNASMN1; SMN2
Hydrochloric Acid SCHEMBL4438046 0.98 HTT (0.86) HTTTGM2FOLH1LMNASMN1; SMN2
SCHEMBL879577 0.98 HTT (0.91) HTTTGM2FOLH1LMNASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 695 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4661890-A1 PTP1B/TC-PTP DUAL INHIBITORS AND PROTEIN DEGRADERS Purdue Research Foundation (US) 2025-12-17 EP claimed
CN-119912519-A Double-target targeted polypeptide compound, preparation method and application 中国人民解放军总医院第一医学中心 2025-05-02 CN claimed
WO-2024167565-A1 PTP1B/TC-PTP DUAL INHIBITORS AND PROTEIN DEGRADERS PURDUE RESEARCH FOUNDATION (US) 2024-08-15 WO claimed
US-10072043-B2 Inhibitors of protein tyrosine phosphatases INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION (US) 2018-09-11 US claimed
US-20160176922-A1 INHIBITORS OF PROTEIN TYROSINE PHOSPHATASES Indiana University Research and Technology Corpora tion (US) 2016-06-23 US claimed
US-9217012-B2 Inhibitors of protein tyrosine phosphatases INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION (US) 2015-12-22 US claimed
US-9045513-B2 Method for preparing precursor used for labeling hepatocyte receptor and containing trisaccharide and DTPA ligand Atomic Energy Council—Institute of Nuclear Energy Research (TW) 2015-06-02 US claimed
US-8809581-B2 Method of making 6-aminocaproic acid as active pharmaceutical ingredient Sunny Pharmtech Inc. (TW) 2014-08-19 US claimed
US-20140046045-A1 METHOD FOR PREPARING PRECURSOR USED FOR LABELING HEPATOCYTE RECEPTOR AND CONTAINING TRISACCHARIDE AND DTPA LIGAND ATOMIC ENERGY COUNCIL - INSTITUTE OF NUCLEAR ENERGY RESEARCH (TW) 2014-02-13 US claimed
US-20140039219-A1 Method of Making 6-Aminocaproic Acid As Active Pharmaceutical Ingredient Sunny Pharmtech Inc. (TW) 2014-02-06 US claimed
US-8481161-B2 Functionalized metal nanoparticle and method for formation of conductive pattern using the same SAMSUNG ELECTRONICS CO., LTD. (KR) 2013-07-09 US claimed
US-20130022628-A1 ACYL PSEUDOPEPTIDES WHICH CARRY A FUNCTIONALIZED AUXILIARY ARM OM PHARMA (CH) 2013-01-24 US claimed
US-20120088720-A1 INHIBITORS OF PROTEIN TYROSINE PHOSPHATASES INDIANA UNIVERSITY RESEARCH & TECHNOLOGY CORPORATI (US) 2012-04-12 US claimed
US-7923110-B2 Metal nanoparticle having a self-assembled monolayer on its surface, and formation of conductive pattern using the same SAMSUNG ELECTRONICS CO., LTD. (KR) 2011-04-12 US claimed
WO-2010118241-A2 INHIBITORS OF PROTEIN TYROSINE PHOSPHATASES INDIANA UNIVERSITY RESEARCH & TECHNOLOGY CORPORATION (US) 2010-10-14 WO claimed
US-20080020317-A1 Novel metal nanoparticle and formation of conductive pattern using the same SAMSUNG ELECTRONICS CO., LTD. (KR) 2008-01-24 US claimed
US-20080003363-A1 Novel metal nanoparticle and method for formation of conductive pattern using the same SAMSUNG ELECTRONICS CO., LTD. (KR) 2008-01-03 US claimed
WO-2026099897-A1 NOVEL LINKERS AND ITS PREPARATION METHODS THEREOF ZYDUS LIFESCIENCES LIMITED (IN) 2026-05-15 WO disclosed
US-3993609-A ACID SENSITIVE AZO PROMOTERS PENNWALT CORPORATION (US) 1976-11-23 US disclosed
US-3935266-A BRADYKININ AND HISTAMINE ANTAGONIST, ANTIINFLAMMATORY TAIHO PHARMACEUTICAL COMPANY, LIMITED (JA) 1976-01-27 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140046045-A1 METHOD FOR PREPARING PRECURSOR USED FOR LABELING HEPATOCYTE RECEPTOR AND CONTAINING TRISACCHARIDE AND DTPA LIGAND HDGF, NR1H4, TRHR HTT 4257/4885TGM2 989/4885FOLH1 693/4885
US-10072043-B2 Inhibitors of protein tyrosine phosphatases PTPRCAP, PTPRF, PTPRS HTT 1387/4885TGM2 1287/4885FOLH1 2209/4885
US-20160176922-A1 INHIBITORS OF PROTEIN TYROSINE PHOSPHATASES PTPRCAP, PTPRF, PTPRS HTT 1387/4885TGM2 1287/4885FOLH1 2209/4885
US-20140039219-A1 Method of Making 6-Aminocaproic Acid As Active Pharmaceutical Ingredient APEH, ACMSD, AASDHPPT HTT 651/4885TGM2 1387/4885FOLH1 627/4885
US-20120088720-A1 INHIBITORS OF PROTEIN TYROSINE PHOSPHATASES PTPRCAP, PTPRF, PTPRS HTT 1387/4885TGM2 1287/4885FOLH1 2209/4885
US-20130022628-A1 ACYL PSEUDOPEPTIDES WHICH CARRY A FUNCTIONALIZED AUXILIARY ARM PIGS, ENPEP, DNPEP HTT 2783/4885TGM2 840/4885FOLH1 524/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.